Reorganising dermatology care: predictors of the substitution of secondary care with primary care

Esther H. A. van den Bogaart 1*, Mariëlle E. A. L. Kroese 1, Marieke D. Spreeuwenberg 1,2, Herm Martens 3, Peter M. Steijlen 3 and Dirk Ruwaard 1

Abstract

Background: The substitution of healthcare is a way to control rising healthcare costs. The Primary Care Plus (PC+) intervention of the Dutch ‘Blue Care’ pioneer site aims to achieve this feat by facilitating consultations with medical specialists in the primary care setting. One of the specialties involved is dermatology. This study explores referral decisions following dermatology care in PC+ and the influence of predictive patient and consultation characteristics on this decision.

Methods: This retrospective study used clinical data of patients who received dermatology care in PC+ between January 2015 and March 2017. The referral decision following PC+, (i.e., referral back to the general practitioner (GP) or referral to outpatient hospital care) was the primary outcome. Stepwise logistic regression modelling was used to describe variations in the referral decisions following PC+, with patient age and gender, number of PC+ consultations, patient diagnosis and treatment specialist as the predicting factors.

Results: A total of 2952 patients visited PC+ for dermatology care. Of those patients with a registered referral, 80.2% (N = 2254) were referred back to the GP, and 19.8% (N = 558) were referred to outpatient hospital care. In the multivariable model, only the treating specialist and patient’s diagnosis independently influenced the referral decisions following PC+.

Conclusion: The aim of PC+ is to reduce the number of referrals to outpatient hospital care. According to the results, the treating specialist and patient diagnosis influence referral decisions. Therefore, the results of this study can be used to discuss and improve specialist and patient profiles for PC+ to further optimise the effectiveness of the initiative.

Keywords: Substitution, Referral decision, Dermatology, Primary care, Outpatient care

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Over the course of the last decade, global expenditure on healthcare as a share of world income has been increasing [1–3]. In the coming decades, healthcare spending is even expected to increase faster than prosperity [2, 4]. The population is ageing, and other explanations for rising expenses, such as technological development and lagging productivity, are likely to remain applicable in the future.

As a way to control costs and the utilisation of healthcare services, several countries (e.g., the Netherlands, the UK, Spain and Scandinavian countries) have implemented a gatekeeper system [5–8]. In these systems, general practitioners (GPs) fulfil an important role in patients’ further access to healthcare [5]. In addition, hospital care and specialist care (except emergency care) are accessible only upon referral from a GP. Since the literature shows that these systems lead to lower use of health services [9], more appropriate and more effective healthcare use [10] and lower expenditures [11], it is beneficial to further strengthen the position of primary care. Therefore, there have been many attempts to improve the effectiveness and efficiency of primary care and the referral process to outpatient hospital care to strengthen healthcare sustainability [12, 13].

Since 1972, healthcare expenditure as a percentage of the gross domestic product (GDP) has been increasing annually in the Netherlands [14]. Therefore, guaranteeing the financial sustainability of the healthcare system in the future is high on the Dutch political agenda [15].

To provide better care at lower costs, so-called pioneer sites have been appointed by the Minister of Health in the Netherlands [16]. At these pioneer sites, health insurers, care providers and patient organisations join forces to establish initiatives to improve the quality of care and reduce healthcare costs. The main goal of these initiatives is to accomplish the three dimensions of the Triple Aim principle proposed by Berwick et al. [17]. This principle focuses on reducing the per capita cost of healthcare, improving the health of the population and improving the patient experience of care. The ‘Blue Care’ pioneer site in the Maastricht-Heuvelland region has implemented several initiatives, one of which is Primary Care Plus (PC+). PC+ uses the concept of substitution, which focuses on shifting specialised care to less expensive and more accessible primary care [18]. The aim of PC+ is to achieve substitution by stimulating integrated care through the facilitating of consultations with medical specialists in the primary care setting. Internationally, comparable models of care are implemented, as for example specialist outreach services and shifted outpatient clinics [12, 13, 19, 20].

One of the specialties involved in PC+ is dermatology. Specialised dermatology care is in high demand due to the increase in the number of patients with dermatological complaints visiting their GPs [21, 22]. Skin conditions are among the most common diseases that are encountered by GPs and for which patients are referred to secondary care [21, 23, 24]. In the Netherlands, 14% of all GP consultations are related to a dermatological disorder [25]. In addition, the number of GP consultations for suspected lesions is increasing by 7.3% annually, and further increases are expected [26, 27]. Along with media campaigns aimed at increasing awareness about the danger of skin cancer and the ageing population [28], the increase in the number of dermatology-related consultations will lead to a growing demand for dermatology-related healthcare services. In addition, GPs often have a lack of dermatological knowledge, which is a reason for diagnostic uncertainty and the experience of difficulties with the diagnosis and treatment of skin disease [29–31]. Moreover, there is large variation in GP referrals to specialised medical care, which is caused by many factors, such as uncertainty about the diagnosis, perceived seriousness of the skin disease and patient preference [32, 33]. GPs’ referral decisions are crucial for the patients’ progress through the healthcare system and, moreover, for the costs of the healthcare system [34]. Therefore, with PC+, the use of specialist medical expertise in primary care can be strengthened and expanded and unnecessary referrals to (expensive) outpatient hospital care can be avoided.

Because of the novelty of PC+ at its initiation in 2014, clear guidelines for GPs about the exact type of patients and complaints to be referred to PC+ were lacking. Therefore, this study explores referral decisions following PC+ dermatology care and the influence of predictive patient and consultation characteristics. The results of this study could contribute to the development of patient profiles and input for the optimisation of the PC+ process.

Methods

Design

This retrospective study uses clinical data on referral decisions from patients who received dermatology care in PC+ from January 2015 to March 2017.

Setting

PC+ is an initiative implemented in the pioneer site Blue Care, located in the Maastricht-Heuvelland region, in which 81 GPs in 55 GP practices care for a population of approximately 170,000 people [35]. In this region, different organisations work together and developed the PC+ intervention to substitute specialised medical care with primary care [36]. After a pilot, in which medical specialist performed consultations in GP practices, PC+ was implemented on a larger scale with two independent
PC+ centres located in the city of Maastricht [37, 38]. This allowed GPs within the region to refer patients to a medical specialist in a neutral primary care setting, with GPs remaining responsible for their patients throughout the whole PC+ care process.

The focus of this study was on dermatology care in the current PC+ setting. Together with orthopaedics, internal medicine, neurology, otolaryngology, ophthalmology, and rheumatology, dermatology has been included in the two PC+ centres from the beginning. Over time, more medical specialties, including paediatrics, gynaecology, urology and a multidisciplinary back pain consultation facility with anaesthesiology and orthopaedics focusing on chronic pain, have been added. Between January 2015 and March 2017, 10,029 patients visited PC+. With 2952 patients, dermatology accounted for almost one-third of all patients in PC+. The distribution of patients among the different medical specialities is shown in Table 1. The low numbers of patients for some medical specialties were mainly caused by their later influx into PC+ and the lack of personnel for some specialties to organise PC+ consultations on a regular basis.

### Intervention

In the PC+ centres, patients with low-complex and non-acute health problems are seen by a medical specialist during a maximum of two consultations, after a referral from their GP. The two PC+ centres operate according to the same method; however, they differ from each other based on the number of consultation hours and the number of different medical specialities. Specialists in PC+ are senior staff specialists working as employees in Maastricht UMC+. The senior staff requirement is part of the standard hourly rate. The costs of the space used by the specialist in PC+ is part of the consultation fee. Furthermore, care in PC+ is claimed as primary care performance, through which it can be offered at a lower price compared to secondary care and consultations are not subject to the patient’s deductible.

The process of referring a patient to dermatology care in PC+ is similar to the process of referring a patient to outpatient hospital care and is shown in Fig. 1. GPs could refer a patient to PC+ when they had doubts about the diagnosis and/or treatment of patients with what appeared to be low-complex and non-acute dermatology-related health problems. Profiles for patients eligible for PC+ were formulated by GPs and dermatologists during the study period and were made accessible online for GPs (see Additional file 1). These profiles were based on the experiences of GPs and medical specialists. In addition, it was assumed that patients referred to PC+ would have been referred to outpatient hospital care in a (hypothetical) situation in which PC+ was not available. The final decision to refer a patient to PC+ or to refer to care as usual (outpatient hospital care) was made based on consultation between the GP and the patient. After the decision was made, the referral was first sent to the Transmural Interactive Patient Platform (TIPP), which plans and registers referrals to medical specialists (either in PC+ or outpatient hospital care). In PC+, patients were seen by a dermatologist, and if necessary, dermatologists were able to perform cryotherapy, skin biopsies, blood tests, microbiology and Wood’s light investigation. Specialists treated patients and/or provided advice for GPs on further treatment strategies.

In this study, data from all patients visiting PC+ for dermatology care were collected.

### Outcome measures

The primary outcome in this study was the referral decision following PC+ (i.e., referral back to the GP or referral to outpatient hospital care). The independent variables were the consultation-related factors: number of PC+ consultations, treating specialist and patient diagnosis. The treating specialist was the specialist who treated the patient during the last PC+ consultation. In addition, the ‘treating specialist’ variable was divided into four categories: the first three categories included the three specialists who had performed the most PC+ consultations, and the fourth category included all other dermatologists working in PC+. The three specialties who had performed the most PC+ consultations had worked in PC+ since the beginning of the study period (January or February 2015). The specialists in the ‘other dermatologists’ category had started working in PC+ at some point during the study period (between January 2015 and October 2016). Patient diagnosis was defined

### Table 1 Number of patients visiting Primary Care Plus for the different medical specialities (N = 10,029)

| Medical specialty      | Number of patients (N) | Start in PC+ |
|------------------------|------------------------|--------------|
| Dermatology            | 29.4% (2952)           | January 2015 |
| Orthopaedics           | 17.0% (1708)           | January 2015 |
| Internal medicine      | 2.9% (291)             | January 2015 |
| Neurology              | 6.4% (638)             | January 2015 |
| Otolaryngology         | 18.1% (1815)           | January 2015 |
| Ophthalmology          | 10.4% (1044)           | January 2015 |
| Rheumatology           | 5.6% (559)             | January 2015 |
| Paediatrics            | 0.5% (50)              | November 2015|
| Gynaecology            | 6.6% (659)             | December 2015|
| Urology                | 1.5% (149)             | March 2016   |
| Back pain consultation facility | 1.6% (163) | November 2016 |
as the diagnosis determined by the specialist during the last PC+ consultation according to the International Classification of Diseases (ICD-10) [39]. This variable was divided into mutually exclusive categories (meaning that patients could be placed in only one diagnosis category): the first ten categories included the ten most common diagnoses in PC+, an 11th category included all other diagnoses and a 12th category was for unknown diagnosis. The corresponding ICD-10 codes of the ten most common diagnoses in PC+ are presented in Additional file 2. In addition, patient age (in years) and gender were used.

**Statistical analysis**

Continuous data are presented as the means and standard deviations (SDs). Categorical data are presented as the counts and percentages. Consultation-related factors and patient-related factors were compared between the two possible referral decisions following a PC+ consultation: (1) referral back to the GP or (2) referral to outpatient hospital care. An independent-samples t-test was used to compare the continuous data, and Pearson's $\chi^2$ test was used to compare the categorical data. $P$-values $\leq 0.05$ were considered statistically significant.

To describe variations in referral decisions, stepwise logistic regression modelling was used, with the decision to refer to outpatient hospital care as a binary yes/no variable. First, univariate logistic regression analysis was used to evaluate the relation between the primary outcome and the independent variables (predictors). Predictors with a $p$-value of $\leq 0.15$ were included in the multivariable logistic regression analysis. For categorical variables, the variable was included when one or more categories had a $p$-value of $\leq 0.15$. In this multivariable model, backwards elimination of the included variables was performed. The results were presented as unadjusted and adjusted odds ratios (ORs and AORs, respectively) with 95% confidence intervals (95% CIs), supplemented by the average marginal effects (AMEs). AMEs represent the difference in the adjusted predictions of the dependent variable relative to the reference group and improve the interpretability of the results [40]. With regard to the categorical variables treating specialist and diagnosis, the category within these variables that had an outpatient hospital care referral rate that was closest to the total average of that variable and that had a reasonable sample size was selected as the reference group. The explained variation in the regression model was measured by the Nagelkerke pseudo $R^2$ [41].

Analyses were performed using SPSS software for Windows version 24.0 (SPSS Inc., Chicago, IL, USA) and R Studio (R Studio, Boston, MA).
Results
Between January 2015 and March 2017, 2952 patients visited PC+ for dermatology care. The referral decision following PC+ was unknown for 140 patients; therefore, these patients were excluded from the analysis. These patients did not differ from the included patients in terms of age or gender (p = 0.748 and p = 0.430, respectively) (see Additional file 3). However, there was a difference in the distribution of treating specialists and diagnoses between the included and excluded patients (p = 0.002 and p ≤ 0.001, respectively).

The remaining 2812 patients had a total of 3355 PC+ consultations (average of 1.19, SD = 0.4 consultations). Following PC+, 80.2% (N = 2254) of the patients were referred back to their GPs, and 19.8% (N = 558) were referred to outpatient hospital care for further treatment/examination (see Table 2).

PC+ patients referred to outpatient hospital care were significantly older than those referred back to their GPs (p ≤ 0.001). There was no significant difference between the two groups with regard to gender (p = 0.563). PC+ patients referred to outpatient hospital care had significantly fewer PC+ consultations (p = 0.045). However, the difference was very small and therefore was not very clinically relevant. In addition, there were differences in the distribution of the referral decision by treating specialist and diagnosis within PC+ (both p ≤ 0.001).

Specialists
In total, 12 different dermatologists worked in PC+ during the study period. However, the number of PC+ consultations held by these specialists varied greatly. There were three specialists who had seen the vast majority of patients. These three specialists saw approximately 90% (N = 2540) of the patients visiting PC+ for dermatology care during the study period.

Predictors of a referral to outpatient hospital care
The results of the univariate and multivariable logistic regression analyses are shown in Table 3. Variables with a p-value ≤0.15 in the univariate analysis (age, number of consultations, treating specialist and diagnosis) were included in the multivariable logistic regression analysis. In the multivariable model only, treating specialist and patient diagnosis were retained as variable that independently influenced a referral to outpatient hospital care.

Table 2 Overview and comparisons of Primary Care Plus patients and consultation characteristics

|                     | Total (N = 2812) | Referred back to GP 80.2% (N = 2254) | Referred to hospital care 19.8% (N = 558) | p-values |
|---------------------|------------------|--------------------------------------|------------------------------------------|----------|
| Age in years (mean ± SD) | 47.7 ± 20.9      | 46.8 ± 21.0                          | 51.5 ± 20.4                              | ≤0.001** |
| Gender – male % (N)  | 41.2 (1159)      | 40.9 (923)                           | 42.3 (236)                               | 0.563    |
| Number of consultations (mean ± SD) | 1.19 ± 0.4     | 1.20 ± 0.4                           | 1.16 ± 0.4                               | 0.045*   |
| Specialist           |                  |                                      |                                          | ≤0.001** |
| Specialist 1% (N)    | 53.6 (1508)      | 84.6 (1276)                          | 15.4 (232)                               |          |
| Specialist 2% (N)    | 25.6 (721)       | 76.0 (548)                           | 24.0 (173)                               |          |
| Specialist 3% (N)    | 11.1 (311)       | 72.3 (225)                           | 27.7 (86)                                |          |
| Other % (N)          | 9.7 (272)        | 75.4 (205)                           | 24.6 (67)                                |          |
| Diagnosis            |                  |                                      |                                          | ≤0.001** |
| Naevi % (N)          | 14.5 (407)       | 77.9 (317)                           | 22.1 (90)                                |          |
| Premalignant dermatosis % (N) | 9.4 (264) | 81.8 (216) | 18.2 (48) |
| Benign tumours % (N) | 8.5 (238)        | 84.9 (202)                           | 15.1 (36)                                |          |
| Other eczema% (N)    | 7.8 (219)        | 93.2 (204)                           | 6.8 (15)                                 |          |
| Acneiform dermatoses % (N) | 6.1 (172) | 87.2 (150) | 12.8 (22) |
| Inflammatory dermatoses % (N) | 5.7 (161) | 70.2 (113) | 29.8 (48) |
| Dermatoses due to microorganisms % (N) | 5.3 (149) | 93.3 (139) | 6.7 (10) |
| Malignant dermatoses % (N) | 5.2 (146) | 26.0 (38) | 74.0 (108) |
| Hair and nail disorders % (N) | 3.7 (103) | 95.1 (98) | 4.9 (5) |
| Pigment disorders % (N) | 3.3 (94) | 85.1 (80) | 14.9 (14) |
| Other % (N)          | 23.2 (653)       | 85.9 (561)                           | 14.1 (92)                                |          |
| Unknown % (N)        | 7.3 (206)        | 66.0 (136)                           | 34.0 (70)                                |          |

* P < 0.05; ** P < 0.001
Patients treated by specialist 2 (AOR 1.88, 95% CI = 1.48–2.39, AME = 0.09), specialist 3 (AOR 1.97, 95% CI = 1.44–2.69, AME = 0.09) or another (less common) specialist (AOR 1.80, 95% CI = 1.29–2.52, AME = 0.08) were more likely to be referred to outpatient hospital care following PC+ than patients treated by specialist 1 (reference group). In addition, patients diagnosed with malignant dermatosis (AOR 12.98, 95% CI = 7.96–21.17, AME = 0.55) or inflammatory dermatoses (AOR 2.12, 95% CI = 1.33–3.38, AME = 0.14) and patients for whom the diagnosis was unknown (AOR 2.24, 95% CI = 1.45–3.45, AME = 0.15) were more likely to be referred to outpatient hospital care than patients diagnosed with premalignant dermatosis (reference group). On the other hand, patients diagnosed with other eczema (AOR 0.36, 95% CI = 0.19–0.66, AME = 0.11) and hair and nail disorders (AOR 0.23, 95% CI = 0.09–0.59, AME = 0.13) were less likely to be referred to outpatient hospital care following PC+ consultations.

The final model explained 19.3% of the variation in PC+ referral decisions (Nagelkerke $R^2 = 0.193$).

**Discussion**

This study explored referral decisions following dermatology care in PC+ and the influence of predictive patient and consultation characteristics on this decision. The results showed that the majority of the patients (80.2%) were referred back to their GPs following a consultation for dermatology care in PC+. This finding is in line with previous research suggesting that initiatives like PC+ have the ability to reduce outpatient hospital care referrals and/or increase the appropriateness of referrals made [13]. However, it is important to verify whether the assumption based on previous research that all patients would have been referred to secondary care if PC+ had not been available is also valid in this case [38].

Furthermore, the results showed that the treating specialist and patient diagnosis independently influenced referral decisions following dermatology care in PC+. Regarding the treating specialist, previous research by van Hoof et al. [37] indicated a profile for appropriate specialists in PC+. According to this profile, specialists should, in addition to having a certain degree of seniority, work according to a generalist approach and have an

| Predictors                  | Unadjusted OR (95% CI) | AME | p-value   | Adjusted OR (95% CI) | AME | p-value   |
|-----------------------------|------------------------|-----|-----------|----------------------|-----|-----------|
| **Age**                     |                        |     |           |                      |     |           |
| Male                        | 1.12 (1.07–1.17)       | 0.02| ≤0.001*** | 1.30 (0.88–1.92)     | 0.04| 0.195     |
| Female                      | 1.06 (0.98–1.18)       | 0.01|           |                      |     |           |
| **Number of consultations** |                        |     |           |                      |     |           |
|                             | 0.79 (0.62–1.00)       | −0.04| 0.054    | 1.80 (1.29–2.52)     | 0.08| ≤0.001*** |
| **Specialist**              |                        |     |           |                      |     |           |
| Specialist 1                | 0.55 (0.45–0.66)       | −0.10| ≤0.001***|                      |     |           |
| Specialist 2                | 1.40 (1.14–1.72)       | 0.06| ≤0.001***| 1.88 (1.48–2.39)     | 0.09| ≤0.001*** |
| Specialist 3                | 1.64 (1.26–2.15)       | 0.09| ≤0.001***| 1.97 (1.44–2.69)     | 0.09| ≤0.001*** |
| Other specialists           | 1.36 (1.02–1.83)       | 0.05| 0.038*    | 1.80 (1.29–2.52)     | 0.08| ≤0.001*** |
| **Diagnosis**               |                        |     |           |                      |     |           |
| Naevi                       | 1.18 (0.91–1.52)       | 0.03| 0.215     | 1.30 (0.88–1.92)     | 0.04| 0.195     |
| Premalignant dermatosis     | 0.89 (0.64–1.23)       | −0.02| 0.477    |                      |     |           |
| Benign tumours              | 0.70 (0.49–1.01)       | −0.05| 0.058*    | 0.83 (0.51–1.33)     | −0.03| 0.433     |
| Other eczema                | 0.28 (0.16–0.47)       | −0.14| ≤0.001***| 0.36 (0.19–0.66)     | −0.11| ≤0.001*** |
| Acneiform dermatoses        | 0.58 (0.36–0.91)       | −0.08| 0.018*    | 0.66 (0.38–1.14)     | −0.05| 0.136     |
| Inflammatory dermatoses     | 1.78 (1.26–2.53)       | 0.11| ≤0.001***| 2.12 (1.33–3.38)     | 0.14| 0.002**   |
| Dermatoses due to microorganisms | 0.28 (0.15–0.53) | −0.14| ≤0.001***| 0.32 (0.16–0.66)     | −0.11| 0.002**   |
| Malignant dermatoses        | 14.00 (9.54–20.53)     | 0.57| ≤0.001***| 12.98 (7.96–21.17)   | 0.55| ≤0.001*** |
| Pigment disorders           | 0.70 (0.39–1.24)       | −0.05| 0.223     | 0.77 (0.40–1.49)     | −0.03| 0.441     |
| Hair and nail disorders     | 0.20 (0.09–0.49)       | −0.16| ≤0.001***| 0.23 (0.09–0.59)     | −0.13| 0.002**   |
| Other diagnosis             | 0.60 (0.47–0.76)       | −0.07| ≤0.001***| 0.71 (0.49–1.05)     | −0.04| 0.086     |
| Unknown diagnosis           | 2.23 (1.65–3.03)       | 0.15| ≤0.001***| 2.24 (1.45–3.45)     | 0.15| ≤0.001*** |

Note: OR Odds ratio, CI Confidence interval, AME Average marginal effects

a P ≤ 0.15; ** P < 0.01; *** P < 0.001

*Age was rescaled such that one unit is equal to 10 years

†Variable not significant in final model

Reference category for the adjusted OR analysis

This study explored referral decisions following dermatology care in PC+ and the influence of predictive patient and consultation characteristics on this decision. The results showed that the majority of the patients (80.2%) were referred back to their GPs following a consultation for dermatology care in PC+. This finding is in line with previous research suggesting that initiatives like PC+ have the ability to reduce outpatient hospital care referrals and/or increase the appropriateness of referrals made [13]. However, it is important to verify whether the assumption based on previous research that all patients would have been referred to secondary care if PC+ had not been available is also valid in this case [38].

Furthermore, the results showed that the treating specialist and patient diagnosis independently influenced referral decisions following dermatology care in PC+. Regarding the treating specialist, previous research by van Hoof et al. [37] indicated a profile for appropriate specialists in PC+. According to this profile, specialists should, in addition to having a certain degree of seniority, work according to a generalist approach and have an

Patients treated by specialist 2 (AOR 1.88, 95% CI = 1.48–2.39, AME = 0.09), specialist 3 (AOR 1.97, 95% CI = 1.44–2.69, AME = 0.09) or another (less common) specialist (AOR 1.80, 95% CI = 1.29–2.52, AME = 0.08) were more likely to be referred to outpatient hospital care following PC+ than patients treated by specialist 1 (reference group). In addition, patients diagnosed with malignant dermatosis (AOR 12.98, 95% CI = 7.96–21.17, AME = 0.55) or inflammatory dermatoses (AOR 2.12, 95% CI = 1.33–3.38, AME = 0.14) and patients for whom the diagnosis was unknown (AOR 2.24, 95% CI = 1.45–3.45, AME = 0.15) were more likely to be referred to outpatient hospital care than patients diagnosed with premalignant dermatosis (reference group). On the other hand, patients diagnosed with other eczema (AOR 0.36, 95% CI = 0.19–0.66, AME = 0.11), dermatoses due to microorganisms (AOR 0.32, 95% CI = 0.16–0.66, AME = 0.11) and hair and nail disorders (AOR 0.23, 95% CI = 0.09–0.59, AME = 0.13) were less likely to be referred to outpatient hospital care following PC+ consultations. The final model explained 19.3% of the variation in PC+ referral decisions (Nagelkerke $R^2 = 0.193$).
attitude that is consistent with the model of substitution. The extent to which the included specialists met this profile was not part of this study. However, the results indicated that the likelihood of patients being referred to outpatient hospital care was influenced by the treating specialists. A reason for this could be that the ability to work in a PC+ setting differs among specialists, and for example, specialists with a less generalist approach may refer patients to outpatient hospital care more often. Therefore, more research is needed to study the ability of specialists to work in PC+.

Regarding the patient diagnosis, the results provide an indication of diagnoses that are suitable for PC+. However, high referral rates to outpatient hospital care do not necessarily indicate that complaints leading to these diagnoses are inappropriate for PC+. For example, regarding malignant dermatoses, PC+ can function as a screening tool to prevent patients with an unjustified suspicion from being referred to hospital care for unnecessary testing and treatment. In addition, PC+ can improve early detection, and patients with more suspicious symptoms can be referred to secondary care for treatment, which may reduce mortality and improve quality of life [42]. In additions, diagnoses such as other eczema, dermatoses due to microorganisms and hair and nail disorders, which have low referral rates to outpatient hospital care, seem particularly suitable for PC+. Nevertheless, these diagnoses will not necessarily always be appropriate for PC+. GPs may also experience a (too) low threshold when referring patients to PC+ [37].

As suggested by van Hoof et al. [37], GPs and specialists should discuss appropriate and inappropriate complaints, symptoms and diseases for PC+. The results of this study can provide input for this discussion and can be used to further develop patient profiles for PC+ (see Additional file 1) if necessary. In addition, when a patient profile for PC+ is composed, appropriate and inappropriate diagnoses should be translated into the International Classification of Primary Care (ICPC) codes [43]. The ICPC-codes are used by every Dutch GP and function to categorise patients’ complaints, symptoms and diseases. One specific ICPC-code could ultimately lead to several diagnoses. In this study, the ICPC-codes were not available. Therefore, the patient diagnosis made by the specialist in PC+ was used as a predictor of the referral decision. Furthermore, the clear provision of advice from specialists to GPs when specialists refer patients back to GPs could contribute to a learning effect among GPs regarding the diagnosis or treatment of dermatology patients and whether to refer to PC+ or outpatient hospital care [44]. This feedback could contribute to bridging the knowledge gap between primary and secondary care [29].

The variation explained by the final model in this study was 19.3%, which implies that a lot of variation is explained by other (party unknown) variables that were not included in the model. According to the literature on GP referrals to hospital care, case-specific factors, such as the nature of the disease and the observed severity, influence the patient referrals [45]. In addition, other patient-associated factors than age and sex, such as the overall health status, insurance coverage, social class, needs and values, pressure for referral and preferences, may influence the referral decision [32, 33, 46].

The results showed that 29.4% of all patients visiting PC+ during the study period had dermatological complaints. This percentage is higher than the 14% of all Dutch patients visiting their GP with a dermatological complaint. However, it is difficult to compare these percentages, since not all medical specialties are represented in PC+. In addition, the medical specialties in PC+ did not have an equal number of consultation hours during the study period due to an unequal influx of patients and a lack of personnel for some medical specialties. Finally, PC+ is focused on a select group of patients with low-complex and non-acute dermatology related health problems who are eligible for this care (see Additional file 1).

Moreover, since PC+ focuses on non-acute and low-complex care, it is assumed that more serious diagnoses, such as malignancies, are not made more often in PC+ than in outpatient hospital care. Epidemiological data on dermatological conditions in primary care and hospital care in the Netherlands [47] and the data for patients diagnosed with malignant dermatoses in the present study are consistent with this observation. In PC+, 5.2% of the patients were diagnosed with malignant dermatoses, compared to 12% of patients in hospital care [47] (see Additional file 4). On the other hand, it is assumed that less serious diagnoses are made more often in PC+ than in outpatient hospital care, since the aim of PC+ is to substitute secondary care with primary care for low-complex care. Based on epidemiological data and the data in the present study, it can be concluded that this is the case for diagnoses such as naevi, benign tumours and inflammatory dermatoses.

In addition, there are various other approaches to reduce outpatient hospital care referrals and/or increase the appropriateness of referrals [13], such as the concept of teledermatology [22, 48] and the employment of GPs with special interests and the implementation of nurse-led services in these kind of settings [23, 49, 50]. Even though these initiatives show generally positive findings in terms of accessibility, waiting time and patient satisfaction [22, 51, 52], researchers also have critiqued the diagnostic accuracy of telemedicine [53], the lack of specific research on patient safety [54], and the limited evidence regarding cost-effectiveness [55].
Limitations
The use of monitoring data limited the amount of information, and therefore predictors, for this study. Extending the data, for example with data from GP practices, can generate more useful information. Examples include the ICPC codes and registration of the severity of the complaints. By expanding the data, the referral decision may be better predicted and more and better information can be given back to GPs and medical specialists in order to improve the efficiency of PC+. In this study, data expansion was not possible because data from GP practices in this region are registered through different systems, which makes data linking complicated.

Additionally, a limited number of specialists were included in the present study. However, differences in the referral decisions of these specialists were observed. It was not possible to include more characteristics of the PC+ specialists in the present study since these variables may affect the anonymity of the specialists involved. However, the results of this study can be used as input for further research. Including more specialists and more characteristics in further research, such as specialist age and work experience, could contribute to more insight into the variation in specialists’ referrals and, therefore, to more input for PC+ the specialist profiles.

Furthermore, follow-up data of patients visiting PC+ for dermatology care were not taken into account. It is possible that patients who were initially referred back to their GPs had follow-up visits for the initial complaint in secondary care shortly having a PC+ consultation. If this pattern were to occur on a significant scale, PC+ would be less appropriate. Therefore, hospital data should be analysed. It is also relevant to determine whether the substitution effect is present in outpatient hospital care.

Finally, the referral decisions following the PC+ consultations of 140 patients and the diagnoses of 206 patients were missing. The results showed that patients excluded from the analysis differed from the included patients in terms of the number of PC+ consultations, and the distribution of treating specialists and diagnoses; therefore, selection bias may exist (see Additional file 3). However, only 140 of the 2952 patients needed to be excluded, which is a relatively low number. Furthermore, incomplete patient cases were partly caused by specialists becoming accustomed to the registration method at the beginning of PC+. Therefore, the degree of selection bias seems limited and it is not expected that the results were considerably influenced.

Conclusion
To conclude, through the referral of a large number of patients back to their GPs following dermatology care in PC+, the number of referrals to hospital care can be limited; thus, dermatology care seems to be suitable for PC+. Both the treating specialist and the patient diagnosis influenced the referral decision. Therefore, the results of this study can be used to discuss and improve profiles for specialists and patients in PC+ to further optimise the effectiveness of the initiative. Besides insight into the influence on quality of care, further research is needed into the costs and volumes of dermatology care, both in PC+ and secondary care to determine if substitution of dermatology care actually occurs and healthcare costs are reduced.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12913-020-05368-2.

Additional file 1. Patient profiles Primary Care Plus. Description of which dermatology complaints/care is appropriate to be referred to Primary Care Plus.
Additional file 2. Top ten diagnoses and ICD-10 codes. Top ten dermatology diagnoses in Primary Care Plus with corresponding ICD-10 codes.
Additional file 3. Comparison of patient categories. Comparison of patients and consultation characteristics of included and excluded patients.
Additional file 4. Distribution of dermatological complaints. Comparison of the distribution of dermatological complaints in primary care, Primary Care Plus and secondary care.

Abbreviations
AME: Average Marginal Effect; AOR: Adjusted odds ratio; CI: Confidence interval; GDP: Gross domestic product; GP: General Practitioner; ICD-10: International Classification of Diseases; ICPC: International Classification of Primary Care; Maastricht UMC+: Maastricht University Medical Centre+; OR: Odds ratio; PC+: Primary Care Plus; SD: Standard deviation; TIPP: Transmural Interactive Patient Platform

Acknowledgements
We acknowledge financial support for the study from the insurers CZ and VGZ and the Province of Limburg. We would also like to acknowledge employees from the Maastricht UMC+ Patient and Care Department (in Dutch, Resultaat Verantwoordelijke Eenheid Patient & Zorg) for their contributions in providing us with data. Finally, we acknowledge the participating GPs of Care In Development, the participating medical specialists of the Maastricht UMC+ and the other people involved in PC+ for their effort. An earlier version of this work was presented at the International Conference on Integrated Care in 2018 [56].

Authors’ contributions
EB, MK, MS and DR designed the study. EB performed the statistical analysis and drafted the manuscript. MK, MS, HH, PS and DR contributed to the interpretation of the data. All authors revised the manuscript and read the final version. The authors approved the final manuscript. All authors have agreed both to be personally accountable for the author’s own contributions and ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Funding
For this study, funding was received from the non-profit private health insurers CZ and VGZ (via the ‘Reinforcing Primary Care South of the Netherlands’ cooperative [in Dutch, Versterking Eerstelijn Zuid-Nederland]) and the Province of Limburg, the Netherlands. The funders had no influence on the research; the research was conducted by independent researchers.
Availability of data and materials
The dataset used and analysed during the current study is available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The data used in this study were already available, and patients were not physically involved in the research. In addition, participant formal consent was not necessary, as this study used de-identified data that were collected as part of the evaluation of patient care, which was confirmed by the Medical Research and Ethics Committee of the Maastricht University Medical Centre (Application number: 14–4–136).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Health Services Research, Care and Public Health Research Institute (CAPHR), Faculty of Health Medicine and Life Sciences, Maastricht University, Duboisdomein 30, Maastricht 6229, GT, The Netherlands.
2Research Centre for Technology in Care, Zuyd University of Applied Sciences, Heerlen, the Netherlands.
3Department of Dermatology and GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Received: 17 December 2018 Accepted: 26 May 2020
Published online: 05 June 2020

References
1. Ortiz-Ospina E, Roser M. Financing Healthcare. https://ourworldindata.org/ financing-healthcare Accessed 3 Apr 2017.
2. OECD. Fiscal sustainability of health systems. Bridging health and finance perspectives. Paris: OECD Publishing; 2015.
3. OECD/EU. Health at a glance: Europe 2016. State of health in the EU cycle. Paris: OECD Publishing; 2016.
4. OECD. What future for health spending?OECD Economics Department; 2013.
5. Schut FT, Verkesscher M. Competition policy for health care provision in the Netherlands. Health Policy. 2017;121(2):126–33.
6. Brequke KR, Nuscheler R, Straume OR. Gatekeeping in health care. J Health Econ. 2007;26(1):149–70.
7. Ktoneman M. Paying general practitioners in Europe. Utrecht: NIVEL; 2011.
8. Ktoneman M, Boerma W, van den Berg M, Groeneewegen P, de Jong J, van Ginneken E. Netherlands: health system review. Health Syst Transit. 2016; 18(2):21–240.
9. Velasco Garmo M, Zentner A, Busse R. The effects of gatekeeping: a systematic review of the literature. Scand J Prim Health Care. 2011;29(1):28–38.
10. Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. Milbank Q. 2005;83(3):547–502.
11. Delnoij D, Van Merode G, Paulus A, Groeneewegen P. Does general practitioner gatekeeping curb health care expenditure? J Health Serv Res Policy. 2000;5(1):22–6.
12. Sibbald B, Pickard S, McLeod H, Reeves D, Mead N, Gemmell I, et al. Moving specialist care into the community: an initial evaluation. J Health Serv Res Policy. 2008;13(4):233–9.
13. Winpenny EM, Mair C, Pitchforth E, King S, Roland M. Improving the effectiveness and efficiency of outpatient services: a scoping review of interventions at the primary-secondary care interface. J Health Serv Res Policy. 2017;22(1):53–64.
14. Bakx P, O'Donnell O, van Doornlaeir O. Spending on health Care in the Netherlands: not going so Dutch. Fisc Stud. 2016;37(3):459–465.
15. Rijksoverheid [Dutch Government]. Naar beter betaalbare zorg. Rapport taskforce Beheerende Zorguitgaven. [working towards more affordable health care. Report taskforce healthcare expenditure]. ’s-Gravenhage: House of Representatives of the Netherlands; 2012. in Dutch.
16. RIVM. National Institute for Public Health and the Environment. Pioneer sites move towards triple aim. Interim report, National Population Health Management Monitoring Scheme. Bilthoven: National Institute for Public Health and the Environment; 2014.
17. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Affairs (Project Hope). 2008;27(3):759–69.
18. van Dijk CE, Korevaar JC, Kooijmans B, de Jong JD, de Bakker DH. The primary-secondary care interface does provision of more services in primary care reduce referrals to medical specialists? Health Policy. 2014; 118(1):48–55.
19. Powell J. Systematic review of outreach clinics in primary care in the UK. J Health Serv Res Policy. 2002;7(3):177–83.
20. Gruen RL, Weeramanthri TS, Knight SS, Ballie RS. Specialist outreach clinics in primary care and rural hospital settings. Cochrane Database Syst Rev. 2004;1:CD003798.
21. Schofield JK, Fleming D, Grindlay D, Williams H. Skin conditions are the commonest new reason people present to general practitioners in England and Wales. Br J Dermatol. 2011;165(5):1044–50.
22. van der Heijden JP, de Keizer NF, Bos JD, Spuls PI, Witkamp L. Teledermatology applied following patient selection by general practitioners in daily practice improves efficiency and quality of care at lower cost. Br J Dermatol. 2011;165(5):1038–65.
23. Salisbury C, Noble A, Horrocks S, Crosby Z, Harrison V, Coast J, et al. Evaluation of a general practitioner with special interest service for dermatology: randomised controlled trial. BMJ. 2005;331(7530):1441–6.
24. Awadalla F, Rosenbaum DA, Camacho F, Fleischer AB Jr, Feldman SR. Dermatologic disease in family medicine. Fam Med. 2008;40(7):507–11.
25. NTVG. Infographic: Huidaandoeningen bij huisarts en dermatoloog [in Dutch]. 2013.
26. Koelink CJ, Kollen BJ, Groenhof F, van der Meer K, van der Heide WK. Skin lesions suspected of malignancy: an increasing burden on general practice. BMC Fam Pract. 2014;15:29.
27. Saper H, Dijk AV, Outer PD, Kranev M, Slobbe L. UV-stirling and gezondheid. Probleemveld en kernbasis bij het RIVM (UV-radiation and health: problem field and knowledge base at the National Institute for public health and the environment (RIVM)). Bilthoven: RIVM. Report 2017–0074; 2017. [In Dutch].
28. Levell NJ, Penart-Lanau AM, Garoij JJ. Introduction of intermediate care dermatology services in Norfolk, England was followed by a 67% increase in referrals to the local secondary care dermatology department. Br J Dermatol. 2012;167(2):443–5.
29. Rubsam ML, Esch M, Baum E, Bosner S. Diagnosing skin disease in primary care: a qualitative study of GPs’ approaches. Fam Pract. 2015;32(5):591–5.
30. Nelson PA, Chew-Graham CA, Griffiths CE, Cordinglly L, Team I, Recognition of need in health care consultations: a qualitative study of people with psoriasis. Br J Dermatol. 2013;168(2):554–61.
31. Federman D, Hogan D, Taylor JR, Caralis P, Korsen RS. A comparison of diagnosis, evaluation, and treatment of patients with dermatologic disorders. J Am Acad Dermatol. 1995;32(5 Pt 1):726–9.
32. O’Donnell CA. Variation in GP referral rates: what can we learn from the literature? Fam Pract. 2000;17(6):462–71.
33. Ringberg U, Flenet N, Forde OH. Examining the variation in GPs’ referral practice: a cross-sectional study of GPs’ reasons for referral. Br J Gen Pract. 2014;64(624):426–33.
34. Davies P, Pool R, Snell G. What do we actually know about the referral process? Br J Gen Pract. 2011;61(593):752–3.
35. ZIO Zorg In Ontwikkeling [Care in Development]. Jaarverslag 2015. [annual report 2015]. Maastricht; 2015. [In Dutch]. Available from: https://www.zio.nl/nieuws/detail/9702/zio-jaarverslag-2015.
36. van den Bogaart EHA, Spreeuwenberg MD, Kroese MEAL, van den Boogaart MW, Boymans TAEJ, Ruwaard D. Referral decisions and its predictors related to orthopaedic care. A retrospective study in a novel primary care setting. PLoS One. 2020;15(11):e0277863.
37. van Hoof SJ, Kroese ME, Kroese MB, Smelt G. What do we actually know about the referral process? Br J Gen Pract. 2016;66(648):1265–65.
38. van den Bogaart EHA, Spreeuwenberg MD, Kroese ME, Meier RI, Hanaerts MM, et al. Substitution of hospital care with primary care: defining the conditions of primary care plus. Int J Integ Care. 2016; 16(1):12.
39. van den Bogaart EHA, Spreeuwenberg MD, Kroese ME, Steeens J, Meier RI, Hanaerts MM, et al. Substitution of outpatient care with primary care: a feasibility study on the experiences among general practitioners, medical specialists and patients. BMC Fam Pract. 2016;17:108.
40. World Health Organization. International classification of diseases (ICD-10). Geneva: World Health Organization; 1991.
40. Norton EC, Dowd BE, Maciejewski ML. Marginal effects—quantifying the effect of changes in risk factors in logistic regression models. JAMA. 2019;321(13):1304–5.

41. Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika. 1991;78(3):691–2.

42. Helfand M, Mahon SM, Eden KB, Frame PS, Orleans CT. Screening for skin cancer. Am J Prev Med. 2001;20(3 Suppl):47–58.

43. Lamberts H, Wood M. World Organization of National Colleges Academies and Academic Associations of General Practitioners/Family Physicians, ICPC Working Party, International Classification of Primary Care Working Party. ICPC - international classification of primary care. Oxford: Oxford University Press; 1987.

44. Sampson R, Barbour R, Wilson P. The relationship between GPs and hospital consultants and the implications for patient care: a qualitative study. BMC Fam Pract. 2016;17:45.

45. Delnoij DMJ, Spreeuwenberg PMM. Variation in GPs’ referral rates to specialists in internal medicine. Eur J Public Health. 1997;7(4):427–35.

46. Shea D, Stuart E, Vasey J, Nag S. Medicare physician referral patterns. Health Serv Res. 1999;34(1):331–48.

47. de Vries E, Kunen M. Huidaandoeningen bij huisarts en dermatoloog (infographic) [skin disorders at the general practitioner and the dermatologist (infographic)]. 2013. ErasmusMC: NTvG; [in Dutch].

48. Lasierna N, Alesanco A, Gilaberte Y, Magillon R, Garcia J. Lessons learned after a three-year store and forward teledermatology experience using internet: strengths and limitations. Int J Med Inform. 2012;81(5):322–43.

49. Courtenay M, Carey N. Nurse-led care in dermatology: a review of the literature. Br J Dermatol. 2006;154(1):1–6.

50. Coast J, Noble S, Noble A, Horrocks S, Asim O, Peters TJ, et al. Economic evaluation of a general practitioner with special interest led dermatology service in primary care. BMJ-Brit Med J. 2005;331(7530):1444–8.

51. Knol A, van den Akker TW, Damstra RJ, de Haan J. Teledermatology reduces the number of patient referrals to a dermatologist. J Telemed Telecare. 2006;12(2):75–8.

52. Eminovic N, de Keizer NF, Wyatt JC, ter Riet G, Peek N, van Weert HC, et al. Teledermatologic consultation and reduction in referrals to dermatologists a cluster randomized controlled trial. Arch Dermatol. 2009;145(5):558–64.

53. Resneck JS, Abrouk M, Steuer M, Tam A, Yen A, Lee I, et al. Choice, transparency, coordination, and quality among direct-to-consumer teledermatology websites and apps treating skin disease. JAMA Dermatol. 2016;152(7):768–75.

54. McLean S, Sheikh A, Cresswell K, Nurmatov U, Mukherjee M, Hemmi A, et al. The impact of telehealthcare on the quality and safety of care: a systematic overview. PLoS One. 2013;8(8):e71238.

55. Roine R, Ohinmaa A, Hailey D. Assessing teledermatology: a systematic review of the literature. Can Med Assoc J. 2001;165(8):765–71.

56. van den Bogaart EHA, Kroese L, Aalje ME, Spreeuwenberg MD, Martens H, Steijlen PM, et al. Reorganising dermatology care: predictors to substitute secondary care with primary care. Int J Integrated Care (IJIC). 2018;18(2):206.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.